Bosentan (Tracleer)



62,5 mg x 2 /day ou 125 mg x 2 /day


  • Hypersensitivity to bosentan or any of the excipients.
  • Hepatic impairment moderate to severe (Class B or C Child-Pugh see section.
  • Baseline values of liver aminotransferases, aspartate aminotransferase (AST) and / or alanine aminotransferase (ALT) levels greater than 3 times the upper limit of normal before treatment initiation.
  • Pregnancy.
  • Association with cyclosporine A and glibenclamide.